Skip to main content
. 2022 May 19;10:e13380. doi: 10.7717/peerj.13380

Figure 11. Evaluation of vaccine construct against other SARS-CoV-2 variants.

Figure 11

(A) Schematic representation of SARS-CoV-2 Surface glycoprotein with different colours denoting different domains along with location of shortlisted BCL, HTL and CTL epitope; NTD: N-terminal domain, RBD: Receptor binding domain, RBM: Receptor binding motif, SD1/2 subdomain 1 and 2, FP: Fusion peptide, HR1: heptad repeat 1, CH: central helix, CD; connector domain, HR2: Heptad repeat 2, TM: transmembrane domain, CT: cytoplasmic tail, S1 and S2 cleavage site are protease cleavage site. DLCFTNVY: BCL epitope, KIADYNYKL: CTL epitope, VKNKCVNFN: HTL epitope. (B) Multiple sequence alignment of different SARS-CoV-2 variants done by CLC Main workbench, showing conserved epitopes (i) BCL epitope, (ii) CTL epitope and (iii) HTL epitope. (C) Phylogenetic tree of 19 SARS-CoV-2 variants. Pango lineage number has been added in the description of variants in the figure.